Infliximab: 불응성 크론병 치료법으로서의 유용성과 Top-down 관해 유도 요법으로서의 가능성
Infliximab: The Benefit for Refractory Crohn Disease and Top-down Induction Therapy in Severe Crohn Disease
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Purpose: The aim of this study is to report the efficacy of infliximab, a monoclonal antibody directed against tumor necrosis factor alpha which is used for both treatment of refractory pediatric Crohn disease (CD) and induction of remission. Methods: Among pediatric patients who were diagnosed with CD at Samsung Medical Center between March 2001 and August 2007, a total of 16 patients were given infliximab to treat conventional therapy- resistant refractory CD and severe active CD for induction of remission. Patients needing maintenance therapy were treated with an infliximab infusion every 8 weeks, and fistulizing CD patients occasionally received the infusion upon the condition that a fistula developed. The efficacy of treatment was assessed by comparing the Pediatric Crohn Disease Activity Index (PCDAI), Hct, ESR, CRP, and serum albumin levels using paired t-test. Results: The male/female ratio was 13：3, and the median age was 13 years (range, 21 months∼15 years). The patients included 7 cases of therapy-resistant refractory CD, 7 cases of severe active CD, and 2 cases of fistulizing CD. Mean PCDAI before infliximab therapy was 34.19±14.96, and mean follow-up PCDAI within 2 to 4 weeks after the last infusion was significantly lower, at 6.88±10.31 (p= 0.000). Hematological markers such as ESR (p=0.000), serum albumin (p=0.016), and CRP (p=0.009) also improved significantly after infusion. Remission was achieved in 2 of 4 patients refractory to conventional therapy. Among 3 steroid-dependent patients, 2 were able to discontinue steroid therapy, and dose reduction was possible in 1 patient. Remission after top-down therapy without prior use of other immunomodulators was achieved in 6 weeks in all 7 of the patients who had severe CD. Nine of ten refractory fistulizing CD patients also showed improvement after infliximab therapy. Conclusion: Infliximab was effective in pediatric refractory CD for induction of remission and maintenance therapy, as well as in severe CD for top-down induction therapy. Furthermore, infliximab has contributed to steroid cessation and dose reduction. Long-term follow-up evaluation is needed to determine safety and efficacy of infliximab in the future.
Abstract
Purpose: The aim of this study is to report the efficacy of infliximab, a monoclonal antibody directed against tumor necrosis factor alpha which is used for both treatment of refractory pediatric Crohn disease (CD) and induction of remission. Methods: Among pediatric patients who were diagnosed with CD at Samsung Medical Center between March 2001 and August 2007, a total of 16 patients were given infliximab to treat conventional therapy- resistant refractory CD and severe active CD for induction of remission. Patients needing maintenance therapy were treated with an infliximab infusion every 8 weeks, and fistulizing CD patients occasionally received the infusion upon the condition that a fistula developed. The efficacy of treatment was assessed by comparing the Pediatric Crohn Disease Activity Index (PCDAI), Hct, ESR, CRP, and serum albumin levels using paired t-test. Results: The male/female ratio was 13：3, and the median age was 13 years (range, 21 months∼15 years). The patients included 7 cases of therapy-resistant refractory CD, 7 cases of severe active CD, and 2 cases of fistulizing CD. Mean PCDAI before infliximab therapy was 34.19±14.96, and mean follow-up PCDAI within 2 to 4 weeks after the last infusion was significantly lower, at 6.88±10.31 (p= 0.000). Hematological markers such as ESR (p=0.000), serum albumin (p=0.016), and CRP (p=0.009) also improved significantly after infusion. Remission was achieved in 2 of 4 patients refractory to conventional therapy. Among 3 steroid-dependent patients, 2 were able to discontinue steroid therapy, and dose reduction was possible in 1 patient. Remission after top-down therapy without prior use of other immunomodulators was achieved in 6 weeks in all 7 of the patients who had severe CD. Nine of ten refractory fistulizing CD patients also showed improvement after infliximab therapy. Conclusion: Infliximab was effective in pediatric refractory CD for induction of remission and maintenance therapy, as well as in severe CD for top-down induction therapy. Furthermore, infliximab has contributed to steroid cessation and dose reduction. Long-term follow-up evaluation is needed to determine safety and efficacy of infliximab in the future.
참고문헌 (26)
- Kugathasan S, "Epidemiologic and clinical characteristics of children with newly diagnosed inflammatory bowel disease in Wisconsin: a statewide population-based study", J Pediatr, 143, pp.525~531 (2003)
- Hyams JS, "Crohn's disease In: Pediatric gastrointestinal and liver disease. 3rd ed", pp.635~660 (2006), Saunders Elsevier
- Kugathasan S, "Pediatric inflammatory bowel disease: clinical and therapeutic aspects", Curr Opin Gastroenterol, 17, pp.350~355 (2001)
- Hanauer SB, "Crohn's disease: step up or top down therapy", Best Pract Res Clin Gastroenterol, 17, pp.131~137 (2003)
- Targan SR, "A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group", N Engl J Med, 337, pp.1029~1035 (1997)
- Hyams JS, "Use of infliximab in the treatment of Crohn's disease in children and adolescents", J Pediatr, 137, pp.192~196 (2000)
- Cezard JP, "A prospective study of the efficacy and tolerance of a chimeric antibody to tumor necrosis factors (remicade) in severe pediatric Crohn disease", J Pediatr Gastroenterol Nutr, 36, pp.632~636 (2003)
- de Ridder L, "Infliximab therapy in 30 patients with refractory pediatric Crohn disease with and without fistulas in the Netherlands", J Pediatr Gastroenterol Nutr, 39, pp.46~52 (2004)
- Wewer V, "Infliximab dependency in a national cohort of children with Crohn's disease", J Pediatr Gastroenterol Nutr, 42, pp.40~45 (2006)
- de Ridder L, "Infliximab as first-line therapy in severe pediatric Crohn disease", J Pediatr Gastroenterol Nutr, 43, pp.388~390 (2006)
- Teitelbaum JE, "Infliximab in pediatric Crohn disease patients with enterovesicular fistulas", J Pediatr Gastroenterol Nutr, 44, pp.279~282 (2007)
- de Ridder L, "Infliximab use in children and adolescents with inflammatory bowel disease", J Pediatr Gastroenterol Nutr, 45, pp.3~14 (2007)
- Hyams J, "Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children", Gastroenterology, 132, pp.863~873 (2007)
- Baldassano R, "Infliximab (REMICADE) therapy in the treatment of pediatric Crohn's disease", Am J Gastroenterol, 98, pp.833~838 (2003)
- Kugathasan S, "Prolonged duration of response to infliximab in early but not late pediatric Crohn's disease", Am J Gastroenterol, 95, pp.3189~3194 (2000)
- Lee NY, "Clinical features and course of Crohn disease in children", Korean J Gastrointest Endosc, 34, pp.193~199 (2007)
- Hyams JS, "Development and validation of a pediatric Crohn's disease activity index", J Pediatr Gastroenterol Nutr, 12, pp.439~447 (1991)
- Otley A, "Assessing activity of pediatric Crohn's disease: which index to use?", Gastroenterology, 116, pp.527~531 (1999)
- Loonen HJ, "A critical assessment of items on the Pediatric Crohn's Disease Activity Index", J Pediatr Gastroenterol Nutr, 36, pp.90~95 (2003)
- Colombel JF, "The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients", Gastroenterology, 126, pp.19~31 (2004)
- Theis VS, "Review article: minimising Tuberculosis during anti-TNF-alpha treatment of inflammatory bowel disease", Aliment Pharmacol Ther, 27, pp.19~30 (2008)
- "TNF 길항제 사용시 잠복결핵 치료지침", pp.1~6 (2004), Korea Food and Drug Administration
- Rosh JR, "Hyams J. Hepatosplenic T-cell lymphoma in adolescents and young adults with Crohn's disease: a cautionary tale?", Inflamm Bowel Dis, 13, pp.1024~1030 (2007)
- Mackey AC, "Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease", J Pediatr Gastroenterol Nutr, 44, pp.265~267 (2007)
- Miele E, "Human antichimeric antibody in children and young adults with inflammatory bowel disease receiving infliximab", J Pediatr Gastroenterol Nutr, 38, pp.502~508 (2004)
- Baert F, "Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease", N Engl J Med, 348, pp.601~608 (2003)